Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Theralase Technologies ( (TSE:TLT) ).
Theralase Technologies’ interim clinical data for its light-activated bladder cancer therapy Ruvidar has been accepted for oral presentation at the 2026 European Association of Urology Congress in London. The presentation will cover Phase II results in BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ, where enrollment is complete and the company positions the treatment as a potential alternative to radical cystectomy for patients who have exhausted standard care options.
The interim data show encouraging safety and efficacy signals, including complete responses in a majority of treated patients and some long-lasting remissions of 15 months to three years after a single treatment. Theralase plans to begin rolling submissions of the Phase II data to Health Canada and the FDA in the third quarter of 2026, with the aim of securing approvals in 2027 and then commercializing Ruvidar initially in Canada and the United States, potentially strengthening its standing in the bladder cancer treatment market.
The most recent analyst rating on (TSE:TLT) stock is a Hold with a C$0.25 price target. To see the full list of analyst forecasts on Theralase Technologies stock, see the TSE:TLT Stock Forecast page.
Spark’s Take on TSE:TLT Stock
According to Spark, TipRanks’ AI Analyst, TSE:TLT is a Neutral.
The score is held down primarily by weak financial performance—very large losses versus a small and declining revenue base, ongoing cash burn, and substantial equity erosion. Technicals provide some support with strong recent momentum (price above major moving averages and positive MACD), but elevated RSI suggests the move may be stretched. Valuation remains unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on TSE:TLT stock, click here.
More about Theralase Technologies
Theralase Technologies Inc. is a Toronto-based clinical-stage pharmaceutical company focused on developing energy-activated small molecule therapies for the destruction of cancer, bacteria and viruses. Its lead program targets Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer, with an innovative light-activated drug, Ruvidar, aimed at providing bladder-sparing treatment options.
Average Trading Volume: 229,935
Technical Sentiment Signal: Strong Buy
Current Market Cap: C$69.41M
For an in-depth examination of TLT stock, go to TipRanks’ Overview page.